Based on the key measurements obtained from Cue Biopharma's financial statements, Cue Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Cue Biopharma's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 2.5 M, whereas Total Current Liabilities is forecasted to decline to about 10.1 M. Key indicators impacting Cue Biopharma's financial strength include:
Investors should never underestimate Cue Biopharma's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cue Biopharma's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cue Biopharma.
Net Income
(47.94 Million)
Cue
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Stock Based Compensation
Begin Period Cash Flow
Change To Account Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Change To Inventory
Change Receivables
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Deferred Long Term Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Non Current Liabilities Other
Short Long Term Debt Total
Current Deferred Revenue
Net Receivables
Inventory
Net Invested Capital
Short Long Term Debt
Net Working Capital
Short Term Debt
Retained Earnings Total Equity
Capital Surpluse
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Reconciled Depreciation
Tax Provision
Probability Of Bankruptcy
Understanding current and past Cue Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cue Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Cue Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Cue Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cue Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cue Biopharma's management manipulating its earnings.
Cue Biopharma Stock Summary
Cue Biopharma competes with Coya Therapeutics,, Lantern Pharma, Fennec Pharmaceuticals, Anixa Biosciences, and INmune Bio. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.
Foreign Associate
Australia
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Cue Biopharma's current stock value. Our valuation model uses many indicators to compare Cue Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cue Biopharma competition to find correlations between indicators driving Cue Biopharma's intrinsic value. More Info.
Cue Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Cue Biopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cue Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Cue Biopharma Systematic Risk
Cue Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cue Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Cue Biopharma correlated with the market. If Beta is less than 0 Cue Biopharma generally moves in the opposite direction as compared to the market. If Cue Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cue Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cue Biopharma is generally in the same direction as the market. If Beta > 1 Cue Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Cue Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cue Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cue Biopharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0814
At present, Cue Biopharma's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Cue Biopharma March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cue Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cue Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cue Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Cue Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cue Biopharma's daily price indicators and compare them against related drivers.
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.